

Serology Test Evaluation Report for "COVID-19 IgM IgG Test" from Shenzhen JetMay Care Limited

October 3, 2020

Contents

1	Intro	oduction	2
	1.1	Panel composition	2
	1.2	Analysis	4
	1.3	Important caveats	4
	1.4	Notes about the evaluation procedure	5
	1.5	Additional notes, anomalies, and clarifications	5
2	Res	ults	6
3	Line	e Data	7
Li	st o	f Tables	
	1	Summary Results	6
	2	Summary Statistics	6
	3	Line Data	7

List of Figures

1	Titer levels for (A) IgM+ and (B) IgG+ samples according to the CDC SARS-CoV-2	
	Spike antigen assay	2

1 Introduction

The COVID-19 IgM IgG Test from Shenzhen JetMay Care Limited was tested on 2020-09-25 at the Frederick National Laboratory for Cancer Research (FNLCR), a Federally Funded Research and Development Center (FFRDC) sponsored by the National Cancer Institute (NCI). Tests were from lot number 20200401. The COVID-19 IgM IgG Test is intended to qualitatively detect IgM and IgG separately.

1.1 Panel composition




Figure 1: Titer levels for (A) IgM+ and (B) IgG+ samples according to the CDC SARS-CoV-2 Spike antigen assay

The test was evaluated against "Panel 3," which includes frozen SARS-CoV-2 antibody-positive serum samples (n = 30) and frozen antibody-negative Anticoagulant Citrate Dextrose Solution Formula A (ACD-A) plasma samples (n = 80). The panel size and composition were chosen to enable a laboratory-based evaluation and to provide reasonable estimates and confidence intervals for test performance in the context of limited sample availability. The sample size is comparable to that of a typical sample size used to support Emergency Use Authorization (EUA) by FDA for tests of this type.

1.1.1 Positive samples

Positive samples used in Panel 3 were from patients previously confirmed to have SARS-CoV-2 infection with a nucleic acid amplification test (NAAT). Time between symptom onset, NAAT testing, and sample collection is not known for all samples. Both SARS-CoV-2 IgM and IgG antibodies are present in all Panel 3 positive samples. The Centers for Disease Control and Prevention (CDC) detected the presence of IgG and IgM antibodies at their laboratory using their SARS-CoV-2 spike enzymelinked immunosorbent assay (ELISA) tests.¹ The presence of antibodies was confirmed at FNLCR using CDC's developed ELISAs (Pan-Ig, IgG, and IgM) as well as an IgG Receptor Binding Domain (RBD) ELISA developed by the Krammer Laboratory at the Icahn School of Medicine at Mount Sinai.² The positive samples selected may not reflect the distribution of antibody levels in patient populations that would be evaluated by such a test. Because all samples are positive for both IgM and IgG, this evaluation cannot verify that tests intended to detect IgM and IgG antibodies separately detect these antibodies independently.

Positive samples were assessed at dilutions of 1:100, 1:400, 1:1600, and 1:6400 by CDC on their Pan-Ig assay, their IgM assay, and their IgG assay. Some samples were run at additional dilutions. Any samples that were positive at a dilution greater than 1:6400 were assigned a titer of 6400 because 1:6400 was the highest dilution at which all positive samples used in these evaluations were assessed.

1.1.2 Negative samples

All Panel 3 negative samples were collected prior to 2020, before the SARS-CoV-2 virus is known to have circulated in the United States. Panel 3 groups include:

- "Negatives" (n = 70): selected without regard for clinical status. This group includes a sample, C0063, that showed reactivity in the Pan-Ig CDC spike ELISA at FNLCR.
- "HIV+" (n = 10): selected from banked serum from HIV+ patients.³ This group includes 3 samples, C0018, C0155, and C0182, that showed reactivity in the IgG RBD ELISA at FNLCR.

All Panel 3 negative samples were assessed at dilutions of 1:100 and 1:400 by CDC on their Pan-Ig assay. A subset of samples was assessed in parallel at additional dilutions and on the CDC IgM

¹See https://www.cdc.gov/coronavirus/2019-ncov/lab/serology-testing.html, which notes "CDC's serologic test has been designed and validated for surveillance and research purposes. It is designed to estimate the percentage of the U.S. population previously infected with the virus – information needed to guide the response to the pandemic and protect the public's health. The CDC test is not currently designed to test individuals who want to know if they have been previously infected with SARS-CoV-2. Commercial tests are available to provide test results to individuals."

²An implementation of this test, the COVID-19 ELISA IgG Antibody Test, has been granted an EUA authorization by FDA for use at the Mount Sinai Laboratory (MSL), Center for Clinical Laboratories, a division of the Department of Databased Madising, New York, NY, Soch et al. (1970)

Pathology, Molecular, and Cell-Based Medicine, New York, NY. See https://www.fda.gov/media/137029/download. ³HIV+ samples were deemed appropriate for inclusion in the panel: (1) to increase the sample size and reduce the confidence interval; and (2) to identify any possibility of cross-reactivity with HIV+ samples. It is anticipated that other types of samples, as they become available, may also be evaluated in any future analyses.

and IgG assays. All Panel 3 negative samples were negative at a dilution of 1:100 on the CDC Pan-Ig assay. These samples were assigned an undetectable titer (represented as zero (0) in the line data) for the Pan-Ig assay, the IgM assay, and the IgG assay.

1.2 Analysis

Samples used in this evaluation were not randomly selected, and sensitivity (PPA) and specificity (NPA) estimates in this report may not be indicative of the real-world performance of the Shenzhen JetMay Care Limited COVID-19 IgM IgG Test. Sensitivity and specificity were calculated for each antibody (e.g., IgM, IgG, IgA, and Pan-Ig, as applicable) separately. In addition, sensitivity and specificity were estimated in a combined manner, where a positive result for any antibody the Shenzhen JetMay Care Limited COVID-19 IgM IgG Test is intended to detect was considered as a positive test result and a negative result meant that a sample tested negative for all antibodies the Shenzhen JetMay Care Limited COVID-19 IgM IgG Test is intended to detect. Positive and negative predictive values were calculated for combined sensitivity and specificity assuming a prevalence of 5%. Cross-reactivity with HIV+ was evaluated, and results are presented separately. If cross-reactivity was detected, the samples with HIV+ were not included in calculations of specificity.

Confidence intervals for sensitivity and specificity were calculated per a score method described in CLSI EP12-A2 (2008).⁴ Confidence intervals for PPV and NPV were calculated using the values from the 95% confidence intervals for sensitivity and specificity. For evaluation of cross-reactivity with HIV+, it was evaluated whether an increased false positive rate among antibody negative samples with HIV was statistically higher than the false positive rate among antibody negative samples without HIV (for this, a confidence interval for the difference in false positive rates was calculated per a score method described by Altman.⁵)

1.3 Important caveats

Sensitivity and specificity estimates in this report may not be indicative of the real world performance of the Shenzhen JetMay Care Limited COVID-19 IgM IgG Test.

These results are based on serum and plasma samples only and may not be indicative of performance with other sample types, such as whole blood, including finger stick blood.

The number of samples in the panel is a minimally viable sample size that still provides reasonable estimates and confidence intervals for test performance, and the samples used may not be representative of the antibody profile observed in patient populations.

⁴CLSI. User Protocol for Evaluation of Qualitative Test Performance; Approved Guideline—Second Edition. CLSI document EP12-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. See https://www.accessdata.fda. gov/scripts/cdrh/cfdocs/cfStandards/detail.cfm?standard__identification_no=31791.

⁵Statistics with Confidence: Confidence Intervals and Statistical Guidelines. (2013). Wiley.

1.4 Notes about the evaluation procedure

- The Shenzhen JetMay Care Limited COVID-19 IgM IgG Test was used per the manufacturer's package insert.
- Devices were tested within any expiration dates provided.
- Devices were not obviously defective / compromised.
- Devices were stored at the FNLCR within their labeled conditions.
- A single operator conducted and read the test.
- The personnel who performed the testing were blinded to the identity / code of the sample and the expected results.
- The testing was performed in a non-clinical laboratory environment.
- Negative and positive samples were ordered randomly and then tested serially.
- The operator trained on the COVID-19 IgM IgG Test with positive and negative controls prior to testing.

1.5 Additional notes, anomalies, and clarifications

The FNLCR provided the following additional information:

Instructions for Use state "Serum/plasma samples should be stored below -20 °C and subjected to one freeze thaw cycle to avoid analyte deteriorate."

2 Results

	Comparator Method Antibody Positive			Collected pr	e-2020	
				Antibody Ne	egative	
COVID-19 lgM & lgG Test	lgM+, IgG+	lgM+, IgG-	lgM-, lgG+	Negative	HIV+	Total
lgM+, lgG+	13					13
IgM+, IgG-	3					3
IgM-, IgG+	4					4
IgM-, IgG-	10			70	10	90
Total	30			70	10	110

Table 1: Summary Results

Table 2: Summary Statistics

Measure	Estimate	Confidence Interval
IgM Sensitivity	53.3% (16/30)	(36.1%; 69.8%)
IgM Specificity	100% (80/80)	(95.4%; 100%)
IgG Sensitivity	56.7% (17/30)	(39.2%; 72.6%)
IgG Specificity	100% (80/80)	(95.4%; 100%)
Combined Sensitivity	66.7% (20/30)	(48.8%; 80.8%)
Combined Specificity	100% (80/80)	(95.4%; 100%)
Combined PPV for prevalence = 5.0%	100%	(35.9%; 100%)
Combined NPV for prevalence = 5.0%	98.3%	(97.3%; 99.0%)
Cross-reactivity with HIV+	0.0% (0/10), not detected	

3 Line Data

In the table below, "Days" refers to "Days from symptom onset to blood collection."

Sample	IgM Result	IgG Result	Control	Sample	Туре	CDC	CDC	CDC	Days	Group
Number				ID		Spike	Spike	Spike		
						Pan-Ig	IgM	lgG		
						Titer	Titer	Titer		
1	Negative	Negative	Pass	C0105	Plasma	0	0	0		Negative
2	Positive	Positive	Pass	D0209	Serum	6400	1600	6400	42	Positive
3	Negative	Negative	Pass	C0137	Plasma	0	0	0		Negative
4	Negative	Negative	Pass	D0023	Plasma	0	0	0		Negative
5	Negative	Negative	Pass	D0086	Plasma	0	0	0		Negative
6	Negative	Negative	Pass	D0326	Serum	400	400	1600		Positive
7	Negative	Negative	Pass	D0168	Serum	400	100	400	24	Positive
8	Negative	Negative	Pass	D0049	Plasma	0	0	0		Negative
9	Negative	Negative	Pass	C0133	Plasma	0	0	0		Negative
10	Negative	Negative	Pass	D0113	Plasma	0	0	0		Negative
11	Negative	Negative	Pass	C0121	Plasma	0	0	0		Negative
12	Negative	Negative	Pass	D0007	Plasma	0	0	0		Negative
13	Negative	Negative	Pass	D0040	Serum	100	100	400	43	Positive
14	Negative	Negative	Pass	C0089	Plasma	0	0	0		HIV+
15	Negative	Negative	Pass	D0192	Plasma	0	0	0		Negative
16	Positive	Positive	Pass	D0386	Serum	6400	6400	6400	20	Positive
17	Positive	Positive	Pass	D0405	Serum	400	400	400	32	Positive
18	Negative	Negative	Pass	C0185	Plasma	0	0	0		Negative
19	Negative	Positive	Pass	D0307	Serum	6400	1600	6400	41	Positive
20	Negative	Negative	Pass	C0182	Plasma	0	0	0		HIV+
21	Negative	Negative	Pass	D0056	Plasma	0	0	0		Negative

Table 3: Line Data

Sample Number	IgM Result	IgG Result	Control	Sample ID	Туре	CDC Spike Pan-Ig Titer	CDC Spike IgM Titer	CDC Spike IgG Titer	Days	Group
22	Negative	Negative	Pass	D0166	Plasma	0	0	0		Negative
23	Positive	Positive	Pass	D0451	Serum	1600	400	1600	35	Positive
24	Positive	Negative	Pass	D0231	Serum	6400	1600	6400	19	Positive
25	Negative	Negative	Pass	C0041	Plasma	0	0	0		Negative
26	Negative	Negative	Pass	C0054	Plasma	0	0	0		HIV+
27	Negative	Negative	Pass	D0123	Plasma	0	0	0		Negative
28	Negative	Negative	Pass	C0032	Plasma	0	0	0		Negative
29	Negative	Negative	Pass	D0135	Plasma	0	0	0		Negative
30	Negative	Negative	Pass	C0196	Plasma	0	0	0		Negative
31	Negative	Negative	Pass	D0187	Plasma	0	0	0		Negative
32	Positive	Positive	Pass	D0498	Serum	1600	400	1600	17	Positive
33	Positive	Positive	Pass	D0344	Serum	6400	1600	6400	27	Positive
34	Negative	Negative	Pass	C0095	Plasma	0	0	0		Negative
35	Negative	Negative	Pass	D0097	Plasma	0	0	0		Negative
36	Positive	Positive	Pass	D0349	Serum	1600	400	6400	19	Positive
37	Negative	Negative	Pass	C0018	Plasma	0	0	0		HIV+
38	Negative	Negative	Pass	D0031	Plasma	0	0	0		Negative
39	Negative	Negative	Pass	D0064	Plasma	0	0	0		Negative
40	Negative	Negative	Pass	C0156	Plasma	0	0	0		Negative
41	Negative	Negative	Pass	D0184	Plasma	0	0	0		Negative
42	Negative	Negative	Pass	C0103	Plasma	0	0	0		Negative
43	Negative	Negative	Pass	C0198	Plasma	0	0	0		Negative
44	Negative	Negative	Pass	C0098	Plasma	0	0	0		Negative
45	Negative	Negative	Pass	C0179	Plasma	0	0	0		Negative
46	Negative	Negative	Pass	C0059	Plasma	0	0	0		Negative

Table 3: Line Data (continued)

Sample Number	IgM Result	IgG Result	Control	Sample ID	Туре	CDC Spike Pan-Ig Titer	CDC Spike IgM Titer	CDC Spike IgG Titer	Days	Group
47	Negative	Negative	Pass	C0063	Plasma	0	0	0		Negative
48	Negative	Negative	Pass	D0102	Serum	400	100	400	24	Positive
49	Negative	Negative	Pass	C0117	Plasma	0	0	0		Negative
50	Negative	Negative	Pass	C0193	Plasma	0	0	0		Negative
51	Negative	Negative	Pass	C0101	Plasma	0	0	0		Negative
52	Negative	Negative	Pass	C0093	Plasma	0	0	0		HIV+
53	Negative	Negative	Pass	D0015	Plasma	0	0	0		Negative
54	Negative	Negative	Pass	D0025	Plasma	0	0	0		Negative
55	Negative	Positive	Pass	D0270	Serum	1600	100	1600	20	Positive
56	Negative	Negative	Pass	D0112	Plasma	0	0	0		Negative
57	Negative	Negative	Pass	D0183	Plasma	0	0	0		Negative
58	Negative	Negative	Pass	C0051	Plasma	0	0	0		Negative
59	Negative	Negative	Pass	C0079	Plasma	0	0	0		Negative
60	Negative	Negative	Pass	D0172	Plasma	0	0	0		Negative
61	Negative	Negative	Pass	C0005	Plasma	0	0	0		Negative
62	Negative	Negative	Pass	C0138	Plasma	0	0	0		HIV+
63	Negative	Negative	Pass	D0142	Plasma	0	0	0		Negative
64	Positive	Positive	Pass	D0493	Serum	1600	400	1600	43	Positive
65	Negative	Negative	Pass	D0141	Plasma	0	0	0		Negative
66	Negative	Negative	Pass	D0148	Plasma	0	0	0		Negative
67	Negative	Negative	Pass	D0038	Serum	400	100	1600	44	Positive
68	Negative	Negative	Pass	D0060	Plasma	0	0	0		Negative
69	Negative	Negative	Pass	D0053	Plasma	0	0	0		Negative
70	Negative	Negative	Pass	C0075	Plasma	0	0	0		Negative
71	Negative	Negative	Pass	C0140	Plasma	0	0	0		Negative
	-	-								-

Table 3: Line Data (continued)

Number ID Spike <t< th=""><th>DC Days pike gG iter 0 400 24 400 23 0 0</th><th>Group HIV+ Positive Positive Negative</th></t<>	DC Days pike gG iter 0 400 24 400 23 0 0	Group HIV+ Positive Positive Negative
5	400 24 400 23 0	Positive Positive Negative
5 5	400 23 0	Positive Positive Negative
	400 23 0	Positive Negative
74 Positive Positive Pass D0455 Serum 1600 1600 64		0
75 Negative Negative Pass D0003 Plasma 0 0	0	
76 Negative Negative Pass C0008 Plasma 0 0		Negative
77 Negative Negative Pass D0497 Serum 400 400 16	600 25	Positive
78 Negative Negative Pass D0178 Plasma 0 0	0	Negative
79 Negative Negative Pass C0197 Plasma 0 0	0	HIV+
80 Positive Positive Pass D0182 Serum 6400 1600 64	100 17	Positive
81 Negative Negative Pass C0109 Plasma 0 0	0	Negative
82 Negative Negative Pass D0085 Plasma 0 0	0	Negative
	400 45	Positive
84 Negative Negative Pass D0091 Serum 400 100 16	600 40	Positive
85 Negative Negative Pass D0170 Plasma 0 0	0	Negative
86 Negative Negative Pass D0020 Serum 1600 400 64	400 42	Positive
87 Negative Negative Pass D0132 Plasma 0 0	0	Negative
88 Negative Negative Pass C0026 Plasma 0 0	0	Negative
89 Negative Negative Pass C0065 Plasma 0 0	0	Negative
90 Negative Negative Pass D0080 Plasma 0 0	0	Negative
	600 19	Positive
92 Negative Negative Pass D0154 Plasma 0 0	0	Negative
93 Negative Negative Pass D0129 Plasma 0 0	0	Negative
94 Negative Negative Pass D0006 Plasma 0 0	0	Negative
95 Negative Negative Pass C0134 Plasma 0 0	0	Negative
96 Negative Negative Pass D0077 Plasma 0 0	0	Negative

Table 3: Line Data (continued)

Sample Number	IgM Result	lgG Result	Control	Sample ID	Туре	CDC Spike Pan-Ig Titer	CDC Spike IgM Titer	CDC Spike IgG Titer	Days	Group
97	Negative	Negative	Pass	C0155	Plasma	0	0	0		HIV+
98	Negative	Negative	Pass	C0099	Plasma	0	0	0		HIV+
99	Positive	Positive	Pass	D0268	Serum	400	100	1600		Positive
100	Positive	Negative	Pass	D0367	Serum	400	400	400	37	Positive
101	Negative	Negative	Pass	C0004	Plasma	0	0	0		Negative
102	Negative	Negative	Pass	C0199	Plasma	0	0	0		Negative
103	Negative	Negative	Pass	C0162	Plasma	0	0	0		Negative
104	Negative	Negative	Pass	C0019	Plasma	0	0	0		Negative
105	Positive	Negative	Pass	D0254	Serum	400	400	1600	34	Positive
106	Negative	Negative	Pass	D0396	Serum	100	100	400	26	Positive
107	Negative	Positive	Pass	D0297	Serum	1600	400	6400	20	Positive
108	Negative	Positive	Pass	D0465	Serum	1600	100	6400	31	Positive
109	Negative	Negative	Pass	D0153	Plasma	0	0	0		Negative
110	Negative	Negative	Pass	D0145	Plasma	0	0	0		Negative

Table 3: Line Data (continued)